<DOC>
	<DOCNO>NCT02391025</DOCNO>
	<brief_summary>This single center cross-sectional imaging study investigate use gallium-68 citrate PET patient metastatic castration-resistant prostate cancer plan undergo metastatic tumor biopsy protocol CC # 125519 . The study population consist patient metastatic castration-resistant prostate cancer undergo metastatic tumor biopsy part clinical protocol CC # 125519 , evidence resistance androgen signal inhibition . The study involve gallium-68 PET scan obtain single time point , follow radiographically-guided metastatic tumor biopsy within 14 day PET scan .</brief_summary>
	<brief_title>Gallium-68 Citrate PET Used Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Gallium citrate</mesh_term>
	<criteria>Male patient histologically confirm prostate cancer Patients must castrate level testosterone ( &lt; 50 ng/dL ) LHRH analogue prior orchiectomy . Presence one metastases standard radiographic scan include crosssectional imaging chest/abdomen/pelvis whole body bone scan safely accessible tumor biopsy judgment treat clinician and/or Interventional Radiology Evidence disease progression PCWG2 criterion within 4 week follow treatment discontinuation potent androgen signal inhibitor , include abiraterone , enzalutamide , ARN509 , combination . Patients must either receive within 4 week discontinuation androgen signal inhibitor time PET image tumor biopsy . Age 18 year old time study entry Platelets &gt; 75,000/Î¼l PT INR PTT &lt; 1.5 time institutional ULN within 14 day prior biopsy . Intervening systemic therapy discontinuation androgen signal inhibitor plan date gallium citrate PET . History radiation therapy target metastatic lesion select tumor biopsy Contraindication biopsy include uncontrolled bleeding diathesis . Active infection within 14 day study enrollment Contraindications MRI ( patient undergo PET/MR study ) , include presence pacemaker , aneurysm clip , implanted device , severe claustrophobia</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Castrate Resistant</keyword>
</DOC>